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S U M M A R Y
Background: Steatosis and insulin resistance induced by hepatitis C virus (HCV) infection are, at least in
part, critical factors for the progression of chronic hepatitis C (CHC) and can inﬂuence the outcome of
antiviral treatment. Silent information regulator 1 (SIRT1) and adenosine monophosphate-activated
protein kinase (AMPK) play a key role in the regulation of hepatic glucose and lipid metabolism. The aim
of this study was to investigate the possible effect of HCV core protein on energy, glucose, and lipid
metabolism of hepatocytes and expression of SIRT1 and AMPK.
Methods: HCV core protein expression plasmid was transfected into HepG2 cells. The level of reactive
oxygen species (ROS) and values of NAD+/NADH and ATP/ADP were detected. Intracellular levels of
triacylglycerol (TG), cholesterol, glucose uptake by hepatocytes, and glucose production were measured.
The expression levels of mRNA and protein of SIRT1 and AMPK were detected. The mRNA levels of SIRT1
and AMPK downstream glucose and lipid metabolism genes were measured.
Results: In HepG2 cells expressing HCV core protein, the level of ROS increased, the value of NAD+/NADH
decreased, the activity and expression levels of mRNA and protein of SIRT1 and AMPK decreased, glucose
uptake and its regulator gene GLUT2 mRNA levels decreased, glucose production and its regulator genes
PEPCK and G6Pase mRNA levels increased, intracellular TG and cholesterol contents and their regulator
gene (SREBP-1c, FAS, ACC, HMGR, and HMGS) mRNA levels increased, the glycolytic gene GK and fatty
acid oxidation genes PPARa and CPT1A mRNA levels decreased.
Conclusions: HCV core protein induces alterations in cellular redox state (decrease in the NAD+/NADH
ratio), which could inﬂuence the activity of SIRT1 and secondarily AMPK, then change the expression
proﬁle of glucose and lipid metabolism-related genes, thereby causing metabolism disorders of
hepatocytes.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Chronic hepatitis C virus (HCV) infection is often associated
with insulin resistance and hepatic steatosis. Insulin resistance has
been implicated in the progression of ﬁbrosis and cirrhosis and the
development of diabetes in chronic hepatitis C (CHC) infection. In a
previous study we demonstrated that insulin resistance and
hyperinsulinemia adversely affected the virological response rates
to anti-HCV therapy,1 and a combination of adenosine monopho-
sphate-activated protein kinase (AMPK) activator metformin,
pegylated interferon a2a (PEG-IFNa2a), and ribavirin improved
insulin sensitivity and increased the sustained virologic response
(SVR) rate with a good safety proﬁle.2 However, the mechanism
underlying these phenomena is not yet fully understood.* Corresponding author. Tel./Fax: +86 0451 86605614.
E-mail address: lijiesun5234@yahoo.com.cn (L.-J. Sun).
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http://dx.doi.org/10.1016/j.ijid.2013.01.027AMPK is a major cellular energy sensor that is activated by
cellular stresses that increase intracellular AMP. In addition to
allosteric regulation by AMP, AMPK is regulated by AMPK kinases
such as proteins LKB1.3 Activated AMPK augments fatty acid
oxidation and decreases glucose output and cholesterol and
triglyceride (TG) synthesis in hepatocytes.4,5 Only a few studies
on the interaction between AMPK and HCV infection have been
reported. It has been stated that HCV infection causes Ser485/491
phosphorylation of AMPK and inhibits the kinase activity of AMPK
and increases lipid accumulation, facilitating HCV replication.6 As
suggested in a recent study,7 a low glucose concentration inhibits
HCV replication along with activation of AMPK, treatment with
AMPK activator suppresses HCV replication, and AMPK inhibitor
has the opposite effect.
Silent information regulator 1 (SIRT1) is a nicotinamide adenine
dinucleotide (NAD+)-dependent histone deacetylase, and it acts as
a modulator of cellular metabolism under different physiological
conditions. Modiﬁcations in NAD+ levels are likely to be the mostses. Published by Elsevier Ltd. All rights reserved.
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with each other. Changes in AMPK activity are associated with
alterations in SIRT1 abundance and activity. SIRT1 activation and
inhibition by pharmacological agents produce parallel changes in
AMPK.9
A considerable number of studies have also suggested that
HCV core protein leads to energy, glucose, and lipid metabolic
disorders.10–12 However, the precise mechanisms are poorly
understood. The role of the SIRT1–AMPK signal pathway has
become a research hotspot for elucidating the mechanism of
diabetes and alcoholic liver disease. Due to the close associa-
tions between chronic HCV infection and diabetes, we
speculated that the SIRT1–AMPK signal pathway may play
an important role in hepatic metabolism disorders caused by
HCV infection. Utilizing HepG2 cells expressing HCV core
protein, we studied the effect of HCV core protein on SIRT1 and
AMPK, and their downstream glucose and lipid metabolism-
related genes, as well as energy, glucose, and lipid metabolism
of hepatocytes.
2. Materials and methods
2.1. Cell culture
HepG2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) (Hyclone, Logan, UT, USA) containing 10% fetal
bovine serum (FBS) (Hyclone), 100 U/ml penicillin (Hyclone),
100 mg/ml streptomycin (Hyclone), and 5.5 mM D-glucose. The
cells were incubated in a humidiﬁed atmosphere of 5% CO2 at 37 8C
and passaged every 3 days by trypsinization.
2.2. Transfections
For transfections, HepG2 cells were used at a conﬂuency of
50–60%. Approximately 5  105 HepG2 cells were seeded into
six-well tissue culture plates at 24 h prior to transfection.
HepG2 cells were transfected with 2 mg of pcDNA3.1()-core
(containing the full-length HCV core gene, kindly provided by
Prof. Jun Cheng, Beijing Titan Hospital, Beijing) or
pcDNA3.1() (Invitrogen, Carlsbad, CA, USA) in Opti-MEM
(Invitrogen) using Lipofectamine 2000 (Invitrogen) in accor-
dance with the manufacturer’s protocol. After 6 h incubation
at 37 8C in 5% CO2, the cells were washed with 1 phosphate-
buffered saline (PBS) and DMEM with serum was added to the
cells. After 48 h of transfection, cells were treated with G418
(500 mg/ml). Following selection for 2 weeks, total popula-
tions of G418-resistant cells were pooled and single-cell
sorted into 96-well plates with a growth medium containing
500 mg/ml G418. Sorted single cells were grown under
selection for an additional 2 weeks and expanded into stable
cell lines. Cells were harvested for HCV core gene expression
analysis by Western blot analysis. In this study, HepG2 cells
transfected with empty vectors (pcDNA3.1()) were used as
control.
2.3. Determination of reactive oxygen species
Cells were plated onto glass coverslips and examined for
reactive oxygen species (ROS) production as a marker for oxidative
stress. They were loaded for 2 h with chloromethyl 20,70-
dichlorodihydroﬂuorescein diacetate (Molecular Probes Inc.,
Eugene, OR, USA) at a ﬁnal concentration of 10 mmol/l.13 The
incorporated radioactivity was measured by liquid scintillation
counter (LS6500; Beckman Coulter, Fullerton, CA, USA). Results
were expressed as relative ﬂuorescence intensity and normalized
to the control cells.2.4. ATP/ADP ratio
The adenosine triphosphate (ATP)/adenosine diphosphate
(ADP) ratio was measured using the ApoSENSOR ADP/ATP Ratio
Assay (Biovision, CA, USA) following the manufacturer’s instruc-
tions. One hundred microliters of reaction mix (5 ml ATP
monitoring enzyme, 95 ml nucleotide-releasing buffer) was added
to the appropriate wells of a 96-well plate for 6 h to burn off low-
level ATP contamination, then the background luminescence was
read. Ten thousand cells were treated with 50 ml of nucleotide-
releasing buffer for 5 min at room temperature with gentle shaking
and transferred to a luminometer plate. ATP levels in the sample
cells were measured in a beta counter after 10 min (data A). ADP
levels were measured after 10 min (data B), then 1 ml ADP-
converting enzyme was added, and the sample was measured
again after 10 min (data C). The ATP/ADP ratio was calculated as:
data A/(data C  data B).
2.5. NAD+/NADH ratio
The NAD+/NADH ratio was measured using the NAD+/NADH
Quantiﬁcation Kit (Biovision). NAD+ was extracted from the cell
pellet by adding 7% perchloric acid with sonication on ice for 5 min.
The sample was centrifuged for 3 min at room temperature and
neutralized with 1 M phosphate buffer and 3 M NaOH solution. The
clear supernatant was mixed with the cycling buffer containing
25 mM Tris–HCl (approximately pH 8), 5 mM MgCl2, 50 mM KCl,
2.25 mM lactate, 54 mM resazurin, and 36 U/ml of diaphorase. The
cycling reaction was initiated with the addition of lactate
dehydrogenase and the increase in the resoruﬁn ﬂuorescence
(with excitation at 560 nm and emission at 590 nm) was measured
continuously using a ﬂuorescent plate reader. NADH was extracted
from cell pellet by adding 0.05 M NaOH/1 mM ethylenediamine-
tetraacetic acid (EDTA) with sonication on ice for 5 min. The alkali
extract was incubated at 60 8C for 30 min and neutralized with
0.1 M HCl and 300 mM phosphate buffer (approximately pH 4.4).
The concentration of NADH was measured ﬂuorometrically using
the cycling assay described above. Standard curves were obtained
by processing the standard NAD+ and NADH samples described
above.
2.6. Measurement of SIRT1 activity
SIRT1 activity was measured using a SIRT1 ﬂuorometric assay
kit (BIOMOL, Plymouth Meeting, PA, USA) in accordance with the
manufacturer’s instructions, with slight modiﬁcations.14 A 25-ml
volume of cell extracts was incubated with 15 ml of Fluor de Lys-
SIRT1 substrate (100 mM) and NAD+ (100 mM) for 30 min at 37 8C.
The reaction was stopped by the addition of 50 ml of developer
reagent and nicotinamide (2 mM), and the ﬂuorescence was
subsequently monitored for 30 min at 360 nm (excitation) and
460 nm (emission). Experimental values were recorded as pmol
converted substrate/mg protein/min. Data were recorded as values
relative to those for mock-transfected HepG2 cells.
2.7. Measurement of AMPKa2 activity
AMPK activity was measured as previously described.15 Brieﬂy,
cell lysates (150 mg protein) were immunoprecipitated with
speciﬁc antibodies against a2 catalytic subunits of AMPK (Bethyl
Laboratories, Montgomery, TX, USA). The kinase reaction was
carried out in 40 mmol/l HEPES (pH 7.0), 0.1 mmol/l synthetic
SAMS peptide, 0.2 mmol/l AMP, 80 mmol/l NaCl, 0.8 mmol/l
dithiothreitol, 5 mmol/l MgCl2, and 0.2 mmol/l ATP (2 mCi of [g-
32P]ATP) for 20 min at 30 8C. Reaction products were spotted on
Whatman P81 ﬁlter paper, the papers were extensively washed in
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scintillation counter. Kinase activity was assessed by incorporated
ATP (pmol) per immunoprecipitated protein (mg) per min. Data
were recorded as values relative to those for mock-transfected
HepG2 cells.
2.8. Glucose uptake by hepatocytes
Cells were cultured in a 12-well plate for the glucose uptake
assay. After serum starvation overnight in 0.1% bovine serum
albumin–DMEM, the cells were subsequently incubated in 1 ml of
PBS containing 100 nM insulin for 30 min at 37 8C. After being
washed with PBS, cells were incubated in 1 ml of PBS containing
1 mCi of 2-deoxy-D-[3H]-glucose/ml (Amersham Life Sciences,
Buckinghamshire, UK) for 5 min. The reaction was stopped by
adding 0.1 mM cytochalasin B on ice. The cells were washed with
ice-cold PBS and solubilized in 0.4 ml of NaOH (0.05 M). The
incorporated radioactivity was measured in 4 ml of scintillation
ﬂuid by liquid scintillation counter.
2.9. Glucose production assay
Culture medium was replaced with glucose production buffer
consisting of glucose-free DMEM, without phenol red, supple-
mented with a gluconeogenic substrate (2 mM sodium pyruvate
and 20 mM sodium lactate). After 24 h of incubation, the medium
was collected, and the total glucose concentration was measured
using a commercial kit (Glucose CII Test Wako, Wako Pure
Chemical Industries, Osaka, Japan) and normalized to the cellular
protein content. As the baseline of glucose production, glucose-free
DMEM with neither sodium pyruvate nor sodium lactate was used.
Glucose production via gluconeogenesis equals the total glucose
production minus the baseline glucose production. The data
recorded were the means of six independent experiments, and the
value for the control cells was arbitrarily expressed as 1.0.
2.10. Measurement of triglyceride and cholesterol content
Cells were maintained in serum-free medium overnight. After
the medium was removed, the cells were washed three times with
PBS and resuspended in 200 ml of PBS. Then lipids were extracted
from 100 ml of PBS by the method of Bligh and Dyer16 and
resuspended in 100 ml of 10% Triton X. The cellular contents of TGTable 1
Sequences of primers used for the real-time polymerase chain reaction
Genes Forward 50–30
SIRT1 CGGAAACAATACCTCCACCTGA 
SREBP-2 ACAACCCATAATATCATTGAGAAACG 
HMGR GCCTGGCTCGAAACATCTGAA 
HMGS GTATGCCCTGGTAGTTGCAGGAG 
AMPKa2 AGCATGGACGGGTTGAAGAG 
GLUT1 TGAACCTGCTGGCCTTC 
GLUT2 TGG GCTGAGGAAGAGACTGT 
SREBP-1c CTTTGCCCACCCTGGTGAGT 
PPARa GACGTGC TTCCTGCTTCATAGA 
FAS GAAACTGCAGGAGC TGTC 
ACC GCTGCTCGGATCACTAGTGAA 
PPAR g GAAATGACCATGGTTGAC 
GK GCCTCCCAAAGCATCTACCTC 
G6Pase CCTGGGGCTGGCTCTCAACTC 
PEPCK CCAGGCAGTGAGGGAGTTTCT 
GAPDH GACAACTTTGGCATCGT 
CPT1A AGACGGTGGAACAGAGGCTGAA 
SIRT, silent information regulator; SREBP, sterol regulatory element binding protein;
protein kinase; GLUT, glucose transporter; PPAR, peroxisome proliferator-activating
glucokinase; G6Pase, glucose 6-phosphatase; PEPCK, phosphoenolpyruvate carboxy
palmitoyl transferase 1.and cholesterol were measured using enzyme reagents (Wako). TG
and total cholesterol contents were expressed as mg of lipid/mg of
cellular protein.
2.11. Real-time PCR analysis for SIRT1, AMPKa2, and glucose and lipid
metabolism-related gene mRNA levels
Total cellular RNA was isolated using the TRIzol reagent
(Invitrogen) following the supplier’s protocol. cDNA was generated
using Quanti Tect Reverse Transcription system (Qiagen, Valencia,
CA, USA). Real-time quantitative PCR was performed on a SYBR
Premix Ex Taq (Takara Bio, Kyoto, Japan) using SYBR green
chemistry in an ABI PRISM 7000 (Applied Biosystems, Foster, CA,
USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as internal control for normalization. The PCR primers for the
ampliﬁcation of SIRT1, AMPKa2, glucose transporter 1 (GLUT1),
GLUT2, glucokinase (GK), phosphoenolpyruvate carboxykinase
(PEPCK), glucose-6-phosphatase (G6Pase), sterol regulatory ele-
ment binding protein (SREBP)-1c, SREBP-2, HMG-CoA reductase
(HMGR), HMG-CoA synthase (HMGS), peroxisome proliferator-
activating receptor (PPAR)a, PPARg, acetyl-coenzyme A carboxyl-
ase (ACC), fatty acid synthesis<!– (FAS), carnitine palmitoyl
transferase-1 (CPT1), and GAPDH are listed in Table 1. PCR
conditions were as follows: 95 8C for 30 s, 58 8C for 30 s, and
extension at 72 8C for 45 s, 40 cycles. The relative gene expression
analysis was carried out using SDS 3.1 software (Applied
Biosystems).
2.12. Western blot
Cells were lysed in buffer (20 mM Tris–HCl, pH 8.0, 1% Nonidet
P-40, 1 mM EDTA, 1 mM ethylene glycol tetraacetic acid (EGTA),
1 mM sodium orthovanadate, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl ﬂuoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, and
1 mg/ml pepstatin). Cell debris was removed by centrifugation at
14 000  g for 15 min at 4 8C, and the cell supernatant was used for
Western blotting. Protein quantiﬁcation was carried out using a
bicinchoninic acid protein assay kit (Thermo Fisher Scientiﬁc,
Rockford, IL, USA). Fifty micrograms of protein was separated by 8%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and electrophoretically transferred to a polyvinylidene
diﬂuoride transfer membrane (Millipore, Billerica, MA, USA). The
membranes were blocked with 5% nonfat dry milk in Tris-bufferedReverse 50–30 PCR product (bp)
GAAGTCTACAGCAAGGCGAGCA 242
TTGTGCATCTTGGCGTCTGT 100
CTGACCTGGACTGGAAACGGATA 135
TGTTGCATATGTGTCCCACGAA 146
GTGGCGACAGAACGATTGAG 409
GCAGCTTCTTTAGCACA 399
AGAGACTGAAGGATGGCTCG 461
GGTTCTCCTGCTTGAGTTTCTGG 315
CCACCATCGCGACCAGAT 374
CACGGAGTTGAGGCGGAT 285
TTCTGCTATCAGTCTGTCCAG 338
CCGCTAGTACAAGTCCTTGTA 437
GCTCCACTG CCCCTCCTCACC 444
AATAGTAGTCCTC CTCAATCC 309
ACTGTGTCTCTTTGCTCTTGG 217
ATGCAGGGATGATGTTCTGG 133
TGAGACCAAACAAAGTGATGATGTCAG 102
 HMGR, HMG-CoA reductase; HMGS, HMG-CoA synthase; AMPK, AMP-activated
 receptor; FAS, fatty acid synthase; ACC, acetyl-coenzyme A carboxylase; GK,
kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CPT1A, carnitine
Figure 1. The expression of HCV core protein by Western blot; 1, mock-transfected
HepG2 cells; 2, HepG2 cells expressing the HCV core protein.
Figure 3. Effect of HCV core protein on activity of SIRT1 and AMPK. The activity of
SIRT1 and AMPK was assayed as described in the Materials and methods section.
The data shown are the means of six independent experiments (abbreviations:
SIRT1, silent information regulator 1; AMPK, AMP-activated protein kinase).
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(anti-phospho-AMPKa (Thr172) monoclonal antibody, anti-
AMPKa antibody (Cell Signaling Technologies, Beverly, MA,
USA), anti-SIRT1 antibody, anti-HCV core monoclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)), followed by
incubation with horseradish peroxidase-conjugated goat anti-
mouse IgG or goat anti-rabbit IgG (Santa Cruz Biotechnology). The
respective protein bands were visualized with an enhanced
chemiluminescence detection system (Perkin Elmer, Waltham,
MA,USA). Protein loading was normalized by probing with anti-
GAPDH monoclonal antibody (Millipore).
2.13. Statistical analysis
Results are expressed as the mean  standard deviation.
Signiﬁcance was determined using the Student’s t-test, and statistical
signiﬁcance was deﬁned as p < 0.05.
3. Results
3.1. Expression of HCV core protein
HCV core protein was detected in HepG2 cells expressing HCV
core protein by Western blot, and not detected in mock-
transfected HepG2 cells (Figure 1).
3.2. Effect of HCV core protein on energy metabolism of hepatocytes
Compared to mock-transfected HepG2 cells, the level of ROS in
HepG2 cells expressing HCV core protein signiﬁcantly increased
(4  0.5 vs. 1  0.1; t = 14.411, p < 0.01) (Figure 2a), and the value of
NAD+/NADH decreased (0.02  0.005 vs. 0.08  0.02; t = 7.348,
p < 0.01) (Figure 2b). There was no difference in the value of ATP/
ADP between the two cell populations (9.3  2.8 vs. 8.2  2.2;
t = 0.757, p > 0.05) (Figure 2a).Figure 2. Effect of HCV core protein on energy metabolism of hepatocytes. The ROS level, 
methods section. The data shown are the means of six independent experiments (abbrev
diphosphate; NADH, nicotinamide adenine dinucleotide).3.3. Effect of HCV core protein on activity and expression of SIRT1
Compared to mock-transfected HepG2 cells, the activity of
SIRT1 (0.2  0.05 vs. 1.0  0.2, t = 9.505, p < 0.01) in HepG2 cells
expressing HCV core protein decreased (Figure 3); the mRNA levels of
SIRT1 (0.4  0.1 vs. 0.8  0.2; t = 4.382, p < 0.01) decreased
(Figure 4); the expression of SIRT1 protein (0.3  0.05 vs. 0.8  0.2;
t = 5.941, p < 0.01) decreased (Figure 5, a and c).
3.4. Effect of HCV core protein on activity and expression of AMPK
Compared to mock-transfected HepG2 cells, the activity of
AMPK (0.3  0.1 vs. 0.9  0.3; t = 4.648, p < 0.01) in HepG2 cells
expressing HCV core protein decreased (Figure 3); the mRNA levels of
AMPKa2 (0.2  0.05 vs. 0.9  0.3; t = 5.715, p < 0.01) decreased
(Figure 4); the expression of p-AMPK protein (0.1  0.02 vs. 0.5  0.1;
t = 9.608, p < 0.01) decreased (Figure 5, b and c). There was no
difference in the expression of AMPK protein between the two cell
populations (0.7  0.2 vs. 0.6  0.3; t = 0.679, p > 0.05).
3.5. Effect of HCV core protein on glucose uptake and glucose
production
Glucose uptake in HepG2 cells expressing HCV core protein was
signiﬁcantly lower than that of mock-transfected HepG2 cells
(count per minute (cpm) 4600  500 vs. 21 000  4600; t = 8.682,
p < 0.01). HepG2 cells expressing HCV core protein produced greater
amounts of glucose than did the control cells (2.6  0.7 vs. 1.0  0.1;
t = 5.543, p < 0.05).ATP/ADP ratio, and NAD+/NADH ratio were assayed as described in the Materials and
iations: ROS, reactive oxygen species; ATP, adenosine triphosphate; ADP, adenosine
Figure 4. Effect of HCV core protein on the expression of SIRT1 and AMPKa2 mRNA.
The expression levels of SIRT1 and AMPKa2 mRNA were measure by RT-PCR as
described in the Materials and methods section. The results have been normalized
to GAPDH and are expressed as the levels relative to control. The data shown are the
means of six independent experiments (abbreviations: SIRT1, silent information
regulator 1; AMPK, AMP-activated protein kinase).
Figure 6. Effect of HCV core protein on mRNA levels of glucose metabolism-related
genes. Transcriptional levels of glucose metabolism-associated genes were
examined by real-time quantitative PCR. The results have been normalized to
GAPDH and are expressed as the levels relative to control. Each data point
represents the mean  standard deviation of six individual experiments
(abbreviations: GLUT, glucose transporter; G6P, glucose-6-phosphatase; GK,
glucokinase; PEPCK, phosphoenolpyruvate carboxykinase).
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related genes
The GLUT2 mRNA level in HepG2 cells expressing HCV core
protein was signiﬁcantly lower than that of mock-transfected
HepG2 cells (0.4  0.1 vs. 1  0.2; t = 6.573, p < 0.01). There was no
signiﬁcant difference in GLUT1 mRNA levels between the two cell
populations (0.9  0.3 vs. 1  0.3; t = 0.577, p > 0.05) (Figure 6).
Compared to mock-transfected HepG2 cells, GK mRNA levels in
HepG2 cells expressing HCV core protein decreased (0.6  0.1 vs.
0.9  0.3; t = 2.324, p < 0.05), the PEPCK mRNA levels (2.8  0.6 vs.
1.0  0.3; t = 6.573, p < 0.01) and the G6Pase mRNA levels (2.6  0.5
vs. 1.0  0.2; t = 7.278, p < 0.01) increased (Figure 6).
3.7. Effect of HCV core protein on triacylglycerol and cholesterol
contents
The intracellular TG content in HepG2 cells expressing HCV core
protein was signiﬁcantly higher than that of mock-transfectedFigure 5. Effect of HCV core protein on the expression of SIRT1 and AMPK protein.
(a) The expression of SIRT1 protein by Western blot. (b) The expression of AMPK and
p-AMPK protein by Western blot. (c) Signal quantiﬁcation by densitometry of SIRT1
and p-AMPK protein normalized to GAPDH expression. The expression levels of
SIRT1 and AMPK protein were measured by Western blot as described in the
Materials and methods section. The data shown are the means of six independent
experiments (abbreviations: SIRT1, silent information regulator 1; AMPK, AMP-
activated protein kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p-
AMPK, phospho-AMPK).HepG2 cells (78.2  18.5 vs. 42.3  10.5 mg/mg; t = 4.134, p < 0.01).
The intracellular cholesterol content in HepG2 cells expressing HCV
core protein was signiﬁcantly higher than that of mock-transfected
HepG2 cells (52.6  12.0 vs. 31.5  8.7 mg/mg; t = 3.487, p < 0.01).
3.8. Effect of HCV core protein on mRNA levels of lipid metabolism-
related genes
As shown in Figure 7, compared to mock-transfected HepG2
cells, the SREBP-1c mRNA levels (1.8  0.5 vs. 0.9  0.3; t = 3.781,
p < 0.01), the FAS mRNA levels (3.1  0.5 vs. 1.0  0.3; t = 8.822,
p < 0.01), the ACC mRNA levels (2.5  0.5 vs. 1.0  0.2; t = 6.823,
p < 0.01), the HMGR mRNA levels (1.8  0.5 vs. 1.0  0.2; t = 3.639,
p < 0.01), and the HMGS mRNA levels (2.7  0.6 vs. 1.0  0.2;
t = 6.584, p < 0.01) in HepG2 cells expressing HCV core protein
increased; whereas the PPARa mRNA levels (0.3  0.1 vs. 1.1  0.3;
t = 6.197, p < 0.01) and CPT1A mRNA levels (0.4  0.1 vs. 1.0  0.3;
t = 4.648, p < 0.01) decreased. The PPARg (0.9  0.3 vs. 1.0  0.2;
t = 0.679, p > 0.05) and SREBP-2 mRNA levels (0.9  0.3 vs. 1.0  0.2;
t = 0.679, p > 0.05) were similar in the two cell populations (Figure 7).
4. Discussion
Hepatic steatosis and insulin resistance caused by HCV
infection are factors that aggravate the progression of liver disease.
Although the pathogenesis of liver disease and metabolic disorders
in HCV infection is poorly understood, oxidative stress due to
mitochondrial respiratory chain dysfunction plays a pivotal role.Figure 7. Effect of HCV core protein on mRNA levels of lipid metabolism-related
genes. Transcriptional levels of lipid metabolism-associated genes were examined
by real-time quantitative PCR. The results have been normalized to GAPDH and are
expressed as the levels relative to control. Each data point represents the mean 
standard deviation of six individual experiments (abbreviations: PPAR, peroxisome
proliferator-activating receptor; HMGR, HMG-CoA reductase; HMGS, HMG-CoA
synthase; FAS, fatty acid synthase; CPT1, carnitine palmitoyl transferase 1, SREBP,
sterol regulatory element binding protein; ACC, acetyl-CoA carboxylase).
Figure 8. Schematic representation of the signaling pathway induced by HCV core protein for metabolism disorders of hepatocytes. HCV core protein induces the alterations
in cellular redox state (the decrease in the NAD+/NADH ratio) and could inﬂuence the activity of SIRT1 and secondarily AMPK, then change the expression proﬁle of glucose
and lipid metabolism-related genes, thereby causing metabolism disorders of hepatocytes. An arrowhead pointing upward (") represents activation and an arrowhead
pointing downward (#) represents the repression of activity.
J.-W. Yu et al. / International Journal of Infectious Diseases 17 (2013) e539–e545e544Our results suggest that HCV core protein induces alterations in the
energy state and redox state of hepatocytes: an increase in ROS
production and decrease in the NAD+/NADH ratio. These ﬁndings
are consistent with those of Wang et al., who showed that HCV core
protein caused dysfunction of the mitochondrial respiratory chain
complex 1 and increased the ROS production or lipid peroxidation
and decreased the NAD+/NADH ratio in core gene transgenic mice
and in HepG2 cells expressing the core protein.10
In the present study, we proved that the activity and abundance
of AMPK signiﬁcantly diminished in HepG2 cells expressing HCV
core protein. There was no signiﬁcant difference in ATP/ADP ratios
between the two cell populations. Our results suggest that the
observed changes in AMPK activity are not associated with
alterations in cellular AMP/ATP ratios. Although the activation of
AMPK appears to be a direct consequence of an increase in the
AMP-to-ATP ratio in many situations, studies in various tissues
have shown that AMPK can be activated or inhibited by
mechanisms that may not involve changes in adenine nucleotide
levels.17 Some scholars have raised the possibility that alterations
in its cellular redox state (the increase in NAD+ levels) contributes
to AMPK activation.18 So the changes of AMPK caused by HCV
infection may be linked to concomitant changes in SIRT1
abundance and activity.
The NAD+-dependent deacetylase SIRT1 is a key regulator of
several aspects of metabolism. Changes in the NAD+/NADH ratio
within a cell, i.e., the cellular redox state, may inﬂuence SIRT1
activity.19 Changes in SIRT1 may regulate AMPK activity.
Overexpression of SIRT1 has been found to increase the
phosphorylation of AMPK and ACC, both in vivo and in vitro,
by a reaction dependent on the AMPK kinase LKB1.20,21
Suchankova et al.,22 found that high glucose-induced changes
in AMPK are linked to alterations in SIRT1 abundance and
activity. We found that SIRT1 activity and abundance decreased
after HCV infection. We speculate that HCV core protein-induced
alterations in the cellular redox state (decrease in the NAD+/
NADH ratio) could inﬂuence the activity of SIRT1 and secondarily
AMPK.
AMPK is a key regulator of both glucose and lipid
metabolism in the liver.23 Activation of AMPK suppresses
SREBP-1c, SREBP-2, and their target genes (ACC and FAS, the
rate-limiting enzymes of fatty acid synthesis; HMGR, the rate-
limiting enzyme for cholesterol synthesis) expression inhepatocytes. Activation of AMPK also up-regulates gene
expression of PPARa and its target gene (CPT1, the rate-
limiting enzyme of fatty acid b-oxidation). In this study, we
found that the transcriptional levels of genes related to fatty
acid and TG biosynthesis (SREBP-1c, FAS, and ACC) and
cholesterol biosynthesis (HMGR and HMGS) were signiﬁcantly
increased; the transcriptional levels of genes related to fatty
acid uptake and b-oxidation (PPARa and CPT1) were markedly
suppressed. Thus HCV core protein induced hepatic TG and
cholesterol accumulation.
Hepatocytes play a crucial role in maintaining plasma
glucose homeostasis by adjusting the balance between hepatic
glucose production and utilization via the gluconeogenic and
glycolytic pathways, respectively. Activation of AMPK
represses gene expression of the PEPCK and G6Pase (the
rate-limiting enzymes of gluconeogenesis), and increases gene
expression of the GK (the rate-limiting enzyme of glycolysis).
Glucose is transported into hepatocytes via GLUT2. Activation
of AMPK increases the glucose uptake by up-regulation of
GLUT2. In this study, we found that HCV core protein promoted
gluconeogenesis via transcriptional up-regulation of the genes
for PEPCK and G6Pase and decreased glycolysis via transcrip-
tional down-regulation of the gene for GK, which may result in
a high concentration of glucose in HCV-infected hepatocytes.
We also found that HCV core protein suppressed cellular
glucose uptake through down-regulation of cell surface
expression of GLUT2.
In conclusion, our study suggests that HCV core protein induces
alterations in cellular redox state (decrease in the NAD+/NADH
ratio), which could inﬂuence the activity of SIRT1 and secondarily
AMPK, then change the expression proﬁle of glucose and lipid
metabolism-related genes, thereby causing metabolism disorders
of hepatocytes (Figure 8). These ﬁndings lay a foundation for the
investigation of SIRT1–AMPK signaling pathway activity as new
target for anti-HCV therapy for CHC patients with insulin
resistance and steatosis.
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